Compare CX & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CX | FMS |
|---|---|---|
| Founded | 1906 | 1996 |
| Country | Mexico | Germany |
| Employees | N/A | N/A |
| Industry | Building Materials | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 13.9B |
| IPO Year | 1999 | 1996 |
| Metric | CX | FMS |
|---|---|---|
| Price | $11.57 | $23.53 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 7 | 2 |
| Target Price | $10.95 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 5.5M | 449.9K |
| Earning Date | 02-05-2026 | 11-04-2025 |
| Dividend Yield | 0.76% | ★ 2.39% |
| EPS Growth | ★ 231.88 | 8.62 |
| EPS | 0.09 | ★ 2.86 |
| Revenue | $15,869,840,000.00 | ★ $23,046,819,198.00 |
| Revenue This Year | $2.25 | $2.13 |
| Revenue Next Year | $5.11 | $2.95 |
| P/E Ratio | ★ $12.19 | $16.05 |
| Revenue Growth | N/A | ★ 2.10 |
| 52 Week Low | $4.89 | $22.05 |
| 52 Week High | $12.04 | $30.46 |
| Indicator | CX | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 58.75 | 44.54 |
| Support Level | $11.58 | $23.83 |
| Resistance Level | $12.04 | $24.12 |
| Average True Range (ATR) | 0.26 | 0.22 |
| MACD | -0.05 | 0.06 |
| Stochastic Oscillator | 54.01 | 26.00 |
Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and also provide related services and reliable construction-related services to customers and communities and maintain business relationships in more than 60 countries throughout the world. The company operates in different parts of the world, with operations in Mexico, the United States, the EMEA region and the SCA&C region.
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.